Geneva, Aug. 6 -- International Clinical Trials Registry received information related to the study (ACTRN12626000946314) titled 'Study to evaluate the safety, effects, and early effectiveness of IDB-1829 in patients with advanced prostate cancer' on July 30.
Study Type: Interventional
Study Design:
Purpose: Treatment
Allocation: Non-randomised trial
Primary Sponsor: Interdict Bio
Condition:
Metastatic Castration-Resistant Prostate Cancer
Metastatic Castration-Resistant Prostate Cancer
Cancer - Prostate
Intervention:
-Participants will receive IDB-1829 orally (by mouth) once daily (QD) in continuous 21-day treatment cycles at four escalating dose levels- DL 1 (1 mg), DL 2 (2 mg), DL 3 (4mg), DL 4 (7 mg).
-Treatment duration will c...